All In Biotech

Free tool

FAERS Monitor: Tivicay

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204790 or its brand name (Tivicay, Dolutegravir Sodium). Reports on generic versions are filed under their own applications.

Reports

9,026

Serious

6,918

77% of reports

Hospitalization

1,965

Death reported

922

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain1,457
  • anxiety1,059
  • emotional distress1,050
  • anhedonia944
  • chronic kidney disease702
  • exposure during pregnancy655
  • fatigue649
  • headache606
  • off label use584
  • renal failure546
  • rash518
  • foetal exposure during pregnancy483
  • pyrexia475
  • hypertension468
  • drug ineffective433

Reports by year received

View as table
YearReports
20102
20121
201325
2014366
2015532
2016534
2017563
2018820
20191,135
20201,061
2021926
2022748
2023792
2024766
2025472
2026283

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anhedoniaSignal94486.881.677,186
exposure during pregnancySignal65524.823.014,829
chronic kidney diseaseSignal70221.720.213,777
emotional distressSignal1,05020.419.219,273
foetal exposure during pregnancySignal48313.912.85,769
renal failureSignal5469.68.94,216
anxietySignal1,0598.78.27,281
painSignal1,4575.55.35,563
hypertensionSignal4685.24.71,577
pyrexiaSignal4753.22.9728
rashSignal5182.82.5596
headacheSignal6062.32.1434
fatigue6491.91.8307
off label use5841.61.4120
drug ineffective4330.80.733

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.